Term
3 alleles --> extensive metabolizers
6 alleles --> intermediate metabolizers
11 alleles --> poor metabolizers |
|
Definition
| CYP2D6 (enzyme that possesses genetic variants affecting drug metabolism) |
|
|
Term
Allele 1 = normal phenotype
Alleles2 and 3 = poor metabolizers |
|
Definition
| Cyp2C19 (enzyme that possesses genetic variants affecting drug metabolism) |
|
|
Term
| No gene expression or dysfunctional protein |
|
Definition
| DNA fragment deletions or insertions into genes (altered gene DNA sequence) |
|
|
Term
| If inserted intact, increased gene expression and protein levels; If not inserted intact --> DNA fragment insertion |
|
Definition
| Gene duplication or increased copy number of genes (altered gene DNA sequence) |
|
|
Term
| most common cause of gene sequence variation; SNP --> phenotypic change and can increase risk of disease; most SNP's occur in introns and rarely cause phenotypic disease |
|
Definition
| Single Nucelotide Polymorphism (Altered Gene DNA sequence) |
|
|
Term
| Hepatic enzyme that conjugates glucuronic acid to bilirubin to increase solubilityand elimination |
|
Definition
| UDP-glucuronosyltransferase 1A1 (UGT1A1) |
|
|
Term
|
Definition
genetic variant UGT1A1*18
(poor/slow metabolizer of irinotecan --> increase drug levels) |
|
|
Term
| labs will show drug levels in normal therapeuic range |
|
Definition
| alteration of drug pharmacodynamics i.e. how patient responds |
|
|
Term
| labs will show non-therapeutic circulating levels of drug and/or active metabolites |
|
Definition
| Abnormal Drug Pharmacokinetics |
|
|
Term
| Mechanisms of management strategies that are used to alter the pathophysiological symptoms |
|
Definition
| Replacement therapy for hormone deficiencies; use of hormones or hormone analogs as pharmacological agents; utilization of agents to antagonize the ADR's of hormone action |
|
|
